Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Quest Medical

This article was originally published in The Gray Sheet

  • News

Executive Summary

Quest Medical: Chairman Richard Gilleland resigns effective Nov. 7. The departure was announced in conjunction with disappointing third quarter financial results showing a 92.6% decline in earnings to $6,748 on sales of $6.5 mil. (down 4.4%). Dallas-based Quest attributes the decline to lower sales at its Advanced Neuromodulation Systems segment. Gilleland, formerly president and CEO of Amsco International, was elected to the Quest board in June and named chairman in July...

Table

View full table

Tags:
Latest Headlines

Warning Letters And Close-Outs – April 2024

To Be (a device) Or Not To Be. That’s The Legal Question

US FDA Grants Teal Health’s At-Home Cervical Screening Device Breakthrough Device Designation

Netherlands Pilots New Scientific Advice Service For Clinical Trials

See All
UsernamePublicRestriction

Register

MT007104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By